Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Slideshows|July 3, 2018
Novel Markers, Glycemic Variability Predict CV Events in Diabetes
Author(s)Kenneth J. Bender, PharmD, MA
From ADA 2018: Two new biomarkers predict CV events independently of conventional risk factors, plus post-hoc analysis of VADT.
Advertisement
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
2
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
3
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
4
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
5